Alpha Emitters Market Size, Share, Growth and Forecast (2026 - 2036)

Alpha Emitters Market Forecast and Outlook By Fact.MR

• In 2025, the alpha emitters market was valued at USD 4.7 billion.
• Based on Fact.MR analysis, demand for alpha-emitting radioisotopes and targeted alpha therapy systems is estimated to grow to USD 5.8 billion in 2026 and USD 47.9 billion by 2036.
• FACT.MR projects a CAGR of 23.4% during the forecast period.

Summary of Alpha Emitters Market

• Market Definition
  • The market covers alpha-emitting radioisotopes including Actinium-225, Radium-223, Astatine-211, and Lead-212 used in targeted alpha therapy, bone metastasis treatment, and radiopharmaceutical production across hospitals, cancer treatment centres, and research institutes globally.
• Demand Drivers
  • FDA approval of Pluvicto in 2022 and expanding Phase III pipelines for Ac-225 targeted constructs are accelerating hospital and cancer centre procurement of alpha-emitting isotopes for oncology treatment programmes through 2025.
  • Bayer AG's Xofigo (Radium-223) sustained commercial expansion in bone metastases treatment across U.S. and European oncology centres, reinforcing institutional radiopharmacy procurement workflows for alpha-emitting radionuclides in 2024.
  • Government-funded isotope infrastructure investment in the United States, France, and South Korea is expanding Ac-225 and At-211 production capacity, reducing supply bottlenecks that constrained clinical programme scaling through 2024.
• Key Segments Analyzed
  • By Radionuclide Type: Actinium-225 leads with approximately 40% share in 2026, driven by high clinical pipeline adoption across targeted alpha therapy oncology programmes globally.
  • By Application: Oncology (Targeted Alpha Therapy) holds approximately 50% share in 2026, anchored by commercial and late-stage clinical radiopharmaceutical programme demand.
  • By End User: Hospitals lead with approximately 46% share in 2026, as the primary treatment administration and nuclear medicine centre procurement point.
  • By Distribution Channel: Direct supply holds approximately 60% share in 2026, driven by regulatory control requirements and isotope half-life constraints necessitating direct producer-to-site logistics.
  • By Isotope Source: Nuclear reactors hold approximately 55% share in 2026, due to large-scale isotope production capacity unavailable from cyclotron or generator systems.
  • By Geography: The United States leads at 23.4% CAGR through 2036, anchored by the deepest targeted alpha therapy pipeline and FDA radiopharmaceutical approval infrastructure.
• Analyst Opinion at FACT.MR
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, ‘CXOs should recognise that the alpha emitters market does not behave like a typical pharmaceutical segment. Clinical efficacy alone is not sufficient. Supply chain security for short half-life isotopes is equally critical. Production, handling, and delivery timelines directly impact treatment viability.’
• Strategic Implications
  • Secure long-term isotope supply agreements with reactor and cyclotron facilities to guarantee Ac-225 and At-211 availability before clinical programme scale-up, as supply constraints are the primary commercial bottleneck.
  • Prioritise FDA and EMA radiopharmaceutical approval pathways for targeted alpha therapy constructs in prostate, thyroid, and neuroendocrine tumour indications to access high-value hospital and cancer centre procurement contracts.
  • Establish direct supply agreements with U.S., UK, German, and French hospital nuclear medicine departments early, bypassing radiopharma distributor intermediaries in high-CAGR markets to capture premium pricing and programme lock-in.
• Methodology
  • Market sizing based on isotope production volumes and treatment cycle pricing by indication, validated against Bayer AG, Novartis AG, and NorthStar Medical Radioisotopes revenue disclosures from 2024 to 2025.
  • Incorporates FDA IND and NDA radiopharmaceutical records, IAEA isotope production benchmarks, NRC licensing data, and EMA clinical trial registry updates from 2024 and 2025.
  • Forecasts factor in isotope production capacity expansion timelines, regulatory approval cycles, clinical trial enrolment rates, and primary interviews with nuclear medicine procurement directors.

Between 2026 and 2036, the market is projected to generate an absolute opportunity of USD 42.1 billion. Growth is transformational rather than incremental. Expansion is driven by targeted alpha therapy commercialization, rising oncology approvals, and investment in isotope production. Limited availability of reactor-grade Actinium-225 remains a major constraint. Regulatory complexity across regions continues to slow product approvals.

Clinical adoption accelerated through 2024 and 2025. Late-stage trials for Ac-225 and Ra-223 therapies attracted strong pharmaceutical investment. However, isotope supply remains the biggest structural risk. Companies without secured long-term supply are being excluded from major oncology contracts. Pricing power is concentrated among supply-assured producers.

The United States leads with 23.4% CAGR through 2036, supported by strong FDA pathways and the deepest clinical pipeline. The United Kingdom follows at 22.7%, driven by NHS oncology expansion and research funding. Germany records 22.3%, supported by advanced radiopharma infrastructure. France grows at 22.0%, driven by isotope production and hospital demand. Italy posts 20.8%, supported by rising clinical adoption. South Korea records 19.5%, driven by cyclotron investment and cancer treatment expansion.

Segmental Analysis

Alpha Emitters Market Analysis by Radionuclide Type

Based on FACT.MR's alpha emitters market report, Actinium-225 is estimated to hold approximately 40% share in 2026. Its dominance reflects a dense clinical development pipeline and its superior alpha energy delivery profile in targeted alpha therapy constructs.

• Novartis Investment: Novartis AG disclosed in its 2024 annual report expansion of its radioligand therapy manufacturing network, including Ac-225 supply agreements with ORNL and global isotope partners, to support late-stage clinical and commercial programmes. The investment targets Ac-225 supply security for its pipeline beyond Pluvicto. [1]
• Astatine-211 Development: Orano Med advanced its At-211-based targeted alpha therapy candidate ONC-001 through Phase I/II clinical evaluation in 2024, demonstrating feasibility of cyclotron-produced At-211 at scale for institutional supply. Results were published at SNMMI 2024. [2]
• Radium-223 Commercial Trend: Bayer AG reported sustained Xofigo (Radium-223 dichloride) revenue in its 2024 pharmaceuticals segment disclosure, with ongoing adoption in castration-resistant prostate cancer with bone metastases across European and U.S. oncology centres. [3]

Alpha Emitters Market Analysis by Application

Based on FACT.MR's alpha emitters market report, oncology (targeted alpha therapy) holds approximately 50% share in 2026. It leads due to accelerating commercial programme launches and a deep Phase II and Phase III pipeline across prostate, thyroid, and neuroendocrine tumour indications.

• Oncology Pipeline Scale: Actinium Pharmaceuticals Inc. disclosed Phase II expansion of its ACTINIUM-4 trial programme in 2024, targeting Ac-225-lintuzumab in acute myeloid leukaemia. The programme expanded trial site enrolment across U.S. academic cancer centres, increasing isotope procurement volumes. [4]
• Bone Metastases Adoption: Bayer AG reported that Xofigo bone metastases indications generated EUR 284 million in revenue in 2024, reflecting sustained hospital procurement across European and North American oncology treatment networks. [3]
• R&D Infrastructure Trend: The U.S. Department of Energy's Isotope Program announced expanded Ac-225 production at Oak Ridge National Laboratory in 2024, specifically to support preclinical and Phase I research supply for academic and pharmaceutical R&D programmes. [5]

Alpha Emitters Market Analysis by End User

Based on FACT.MR's alpha emitters market report, hospitals hold approximately 46% share in 2026. Hospitals dominate because nuclear medicine departments are the primary licensed sites for radiopharmaceutical preparation and administration.

• Hospital Network Expansion: Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center expanded their nuclear medicine radiopharmacy capacity in 2024, adding Ac-225 targeted alpha therapy capability to support increased clinical trial and compassionate use administration. [6]
• Cancer Centre Procurement: Telix Pharmaceuticals disclosed in its 2024 investor update that its radiopharmaceutical supply agreements for cancer treatment centres in the U.S. and Australia expanded, including supply arrangements for alpha-emitting isotope-based diagnostic and therapeutic candidates. [7]
• Research Institute Demand: The European Commission's European Innovative Medicines Initiative allocated funding in 2024 to Ac-225 and At-211 research consortia across European university hospitals, increasing institutional isotope procurement for preclinical and translational research. [8]

Alpha Emitters Market Analysis by Distribution Channel

Based on FACT.MR's alpha emitters market report, direct supply holds approximately 60% share in 2026. The short physical half-life of Ac-225 (10 days) and At-211 (7.2 hours) makes rapid, direct logistics from production site to clinical facility operationally mandatory.

• NorthStar Direct Supply: NorthStar Medical Radioisotopes expanded its direct supply logistics network for Ac-225 in 2024, including same-day delivery capability to partnered U.S. hospital nuclear medicine departments. The expansion was part of its DOE-supported supply infrastructure programme.
• Radiopharma Distributor Trend: Curium Pharma extended its radiopharmacy distribution network across European hospital nuclear medicine departments in 2024, including new site agreements for Ra-223 and Ac-225 conjugate delivery in France, Germany, and the UK. [9]
• Research Supply Networks: The IAEA's Programme of Action for Cancer Therapy expanded its research isotope supply coordination in 2025, supporting low- and middle-income country research institutes with cyclotron-based alpha emitter access through coordinated supply networks.

Alpha Emitters Market Analysis by Isotope Source

Based on FACT.MR's alpha emitters market report, nuclear reactors hold approximately 55% share in 2026. Reactor-based Ac-225 production via U-233 or Ra-226 irradiation yields volumes that cyclotron or generator systems cannot match.

• Reactor Capacity Investment: The U.S. Department of Energy announced USD 150 million in isotope infrastructure investment in 2024, including expanded Ac-225 production at Oak Ridge National Laboratory targeting clinical and commercial radiopharmaceutical supply for U.S. hospital programmes.
• Cyclotron Source Development: IBA (Ion Beam Applications) deployed additional cyclotron infrastructure for At-211 production at partner sites in 2024, targeting pharmaceutical company R&D supply contracts in Europe and North America as At-211 clinical demand increased.
• Generator System Trend: Actinium Systems Inc. reported in 2024 progress on its Ra-225/Ac-225 generator platform, which enables on-site Ac-225 generation from Ra-225 precursors at hospital radiopharmacies, reducing logistics dependency on centralized reactor production.

Drivers, Restraints, and Opportunities

FACT.MR analysts observe the alpha emitters market is structurally shaped by the convergence of targeted radiopharmaceutical oncology and constrained isotope supply infrastructure.

The core tension lies between clinical pipeline velocity and isotope supply scalability. Late-stage oncology programmes are advancing faster than reactor capacity expansions. Isotope producers with secured supply positions command premium pricing and exclusive programme supply agreements.

• FDA Radioiopharmaceutical Pipeline: The FDA approved Pluvicto (lutetium-177 PSMA) in 2022, establishing a clinical and regulatory precedent that is accelerating Ac-225-PSMA Phase III investments by Novartis and competitors. The FDA's 2024 radiopharmaceutical guidance update streamlined IND submission requirements for alpha therapy candidates, shortening development timelines.
• European Isotope Infrastructure Investment: The European Commission's European Atomic Energy Community framework supported EUR 120 million in nuclear medicine isotope production upgrades across Belgium, Netherlands, and France in 2024. These investments targeted Ac-225 and At-211 production scale-up at SCK CEN, NRG, and CEA facilities to meet growing clinical demand.
• Asia Pacific Cancer Burden Growth: South Korea's Ministry of Health and Welfare reported 280,000 new cancer cases in 2024. This is driving oncology treatment infrastructure investment and creating demand for targeted alpha therapy procurement at National Cancer Centre and major hospital networks.

Regional Analysis

The alpha emitters market is assessed across North America, Europe, Asia Pacific, Latin America, and Middle East and Africa, covering 40+ countries segmented by clinical trial infrastructure, regulatory approval pathways, isotope production capacity, and hospital nuclear medicine procurement maturity. The full report offers market attractiveness analysis by region and country.

Source: Fact.MR (FACT.MR) analysis, based on proprietary forecasting model and primary research

North America Alpha Emitters Market Analysis

North America is the clinical development and regulatory approval epicentre for targeted alpha therapy. The United States anchors global pipeline activity, FDA radiopharmaceutical approval workflows, and DOE isotope supply investment. Novartis AG and NorthStar Medical Radioisotopes lead regional supply.

• United States: Demand for alpha emitters in the United States is projected to rise at 23.4% CAGR through 2036. The FDA's 2024 radiopharmaceutical guidance update streamlined IND requirements for alpha therapy candidates, accelerating Phase II and III trial commencement at academic medical centres. The U.S. Department of Energy announced a USD 150 million isotope infrastructure investment in 2024, targeting Ac-225 production scale-up at Oak Ridge National Laboratory to meet oncology programme supply needs.

FACT.MR's analysis of the alpha emitters market in North America consists of country-wise assessment that includes the United States, Canada, and Mexico. Readers can find FDA approval pipeline data, DOE isotope infrastructure investment flows, clinical trial enrolment benchmarks, and hospital nuclear medicine procurement trends.

Europe Alpha Emitters Market Analysis

Europe is the radiopharmaceutical manufacturing and reactor isotope production backbone for global alpha emitter supply. Germany and France anchor reactor and clinical infrastructure. Curium Pharma and Orano Med lead regional supply and distribution. Procurement is driven by hospital nuclear medicine departments and academic oncology trial programmes under EMA regulatory frameworks.

• United Kingdom: United Kingdom is projected to rise at 22.7% CAGR through 2036. NHS England's cancer strategy update in 2024 included targeted radionuclide therapy expansion within NHS hospital oncology departments, generating structured procurement demand for Ra-223 and Ac-225 therapy programmes. The Medical Research Council awarded GBP 18 million in 2024 to CRUK-partnered At-211 and Ac-225 translational research consortia at King's College London and the Christie NHS Foundation Trust, expanding institutional isotope procurement for trial supply.
• Germany: Germany is projected to rise at 22.3% CAGR through 2036. Germany's dense radiopharmaceutical manufacturing base includes DKFZ Heidelberg and TUM Munich as leading Ac-225 therapy research and clinical trial sites, generating significant institutional isotope procurement outside commercial distribution. The German Federal Ministry of Education and Research funded targeted alpha therapy research expansion in 2024 under its National Decade Against Cancer programme, allocating EUR 25 million to academic and hospital trial programmes.
• France: Alpha emitters in France is projected to rise at 22.0% CAGR through 2036. France benefits from domestic Ac-225 and alpha isotope production capability at the CEA (Commissariat à l'Énergie Atomique), which supplies hospital nuclear medicine departments and Orano Med's radiopharmaceutical development programmes. The French National Cancer Institute (INCa) approved targeted alpha therapy research funding in 2024 for multi-centre clinical trials at CHU Lyon, CHU Bordeaux, and Institut Curie, increasing hospital procurement of Ac-225 constructs.
• Italy: Demand for alpha emitters in Italy is projected to rise at 20.8% CAGR through 2036. Italy's nuclear medicine procurement is centred in university hospital networks including Istituto Europeo di Oncologia in Milan and Policlinico Sant'Orsola in Bologna, both of which initiated Ac-225 targeted therapy clinical programmes in 2024.

FACT.MR's analysis of the alpha emitters market in Europe consists of country-wise assessment that includes Germany, France, the United Kingdom, Italy, Spain, and Rest of Europe. Readers can find EMA regulatory timeline data, reactor isotope production benchmarks, hospital nuclear medicine procurement trends, and clinical trial site expansion data by country.

Asia Pacific Alpha Emitters Market Analysis

Asia Pacific is a high-growth clinical adoption and isotope infrastructure investment region for alpha emitters. South Korea leads on cyclotron investment and cancer centre procurement scale. Japan supports precision clinical adoption. China is expanding nuclear medicine infrastructure under government-funded oncology programmes. Telix Pharmaceuticals and regional cyclotron operators anchor supply networks.

• South Korea: South Korea is projected to rise at 19.5% CAGR through 2036. South Korea's Ministry of Science and ICT invested KRW 85 billion in 2024 in medical isotope cyclotron infrastructure, including At-211 production capability at Korea Institute of Radiological and Medical Sciences, targeting clinical supply for hospital cancer treatment centres. The National Cancer Centre Korea initiated Ac-225 targeted alpha therapy feasibility programmes in 2024, procuring isotopes under direct supply agreements with international producers.

FACT.MR's analysis of the alpha emitters market in Asia Pacific consists of country-wise assessment that includes China, Japan, South Korea, India, ASEAN, and Australia and New Zealand. Readers can find cyclotron infrastructure investment data, cancer treatment centre procurement benchmarks, clinical trial enrolment trends, and isotope import regulation updates by country.

Competitive Aligners for Market Players

The alpha emitters market is shaping up very differently from traditional pharma, and companies are adjusting their strategies accordingly. Success here is not just about having a strong drug pipeline. It is equally about securing reliable isotope supply. Players such as Bayer AG, Novartis AG, and Actinium Pharmaceuticals, Inc. are aligning their investments toward both clinical development and isotope access. This dual focus is becoming essential.

A major competitive aligner is vertical integration. Companies are moving closer to reactor and cyclotron infrastructure to ensure consistent availability of isotopes like Actinium-225. Partnerships with nuclear facilities and long-term supply agreements are becoming common. Without this, even strong therapies struggle to scale commercially.

Another key shift is toward early-stage collaboration. Drug developers are working with isotope producers much earlier in the pipeline. This helps secure supply before late-stage trials, where demand increases sharply. It also reduces the risk of delays during regulatory approval and commercial launch. Logistics capability is also emerging as a differentiator. These isotopes have very short half-lives, so timing is critical. Firms that can manage production, transport, and hospital delivery efficiently are gaining trust from healthcare providers. Some players are focusing purely on isotope production, while others concentrate on radiopharmaceutical development. The most competitive companies are those that can connect both sides effectively. In this market, control over supply is just as valuable as innovation in therapy.

Key Players

• Bayer AG
• Novartis AG
• Curium Pharma
• NorthStar Medical Radioisotopes
• Orano Med
• Actinium Pharmaceuticals Inc.
• Telix Pharmaceuticals

Bibliography

• [1] Novartis AG. Annual Report 2024: radioligand therapy manufacturing network expansion, Ac-225 supply agreements with ORNL and international isotope partners for clinical and commercial pipeline supply. February 2025. novartis.com/investors
• [2] Orano Med. SNMMI 2024 Conference Presentation: ONC-001 At-211-based targeted alpha therapy Phase I/II results and cyclotron-produced Astatine-211 scale-up feasibility. June 2024. oranomed.com/news
• [3] Bayer AG. Pharmaceuticals Division Disclosure 2024: Xofigo (Radium-223 dichloride) revenue performance and bone metastases indication adoption across European and U.S. oncology centres. December 2024. bayer.com/investors
• [4] Actinium Pharmaceuticals Inc. Clinical Programme Update 2024: ACTINIUM-4 Phase II trial expansion for Ac-225-lintuzumab in acute myeloid leukaemia across U.S. academic cancer centres. October 2024. actiniumpharma.com/investors
• [5] U.S. Department of Energy Isotope Program. Isotope Infrastructure Investment Announcement: USD 150 million Ac-225 production capacity expansion at Oak Ridge National Laboratory for clinical and commercial radiopharmaceutical supply. July 2024. energy.gov/science/isotopes
• [6] Memorial Sloan Kettering Cancer Center. Nuclear Medicine Capacity Expansion Disclosure: Ac-225 targeted alpha therapy radiopharmacy capability addition supporting clinical trial and compassionate use administration. September 2024. mskcc.org/news
• [7] Telix Pharmaceuticals. 2024 Investor Update: radiopharmaceutical supply agreement expansion for cancer treatment centres in the U.S. and Australia including alpha-emitting isotope-based therapeutic candidates. November 2024. telixpharma.com/investors
• [8] European Commission. European Innovative Medicines Initiative Funding Announcement 2024: Ac-225 and At-211 research consortium grants for European university hospital translational research programmes. March 2024. ec.europa.eu/research
• [9] Curium Pharma. Distribution Network Update 2024: European hospital nuclear medicine Ra-223 and Ac-225 conjugate delivery network expansion across France, Germany, and the UK. August 2024. curiumpharma.com/news

This Report Addresses

• Strategic intelligence on alpha emitter demand across radionuclide type, application, end user, distribution channel, and isotope source segments in oncology, bone metastases, and radiopharmaceutical production globally.
• Market size forecast from USD 5.8 billion in 2026 to USD 47.9 billion by 2036 at a CAGR of 23.4%, with USD 42.1 billion in absolute dollar opportunity.
• Growth opportunity mapping across U.S. DOE isotope infrastructure investment, European Atomic Energy Community production upgrades, UK NHS oncology procurement, German BMBF cancer research funding, and South Korea cyclotron capacity expansion.
• Segment analysis by radionuclide type (Ac-225, Ra-223, At-211, Pb-212), application (targeted alpha therapy, bone metastases, R&D, radiopharmaceutical production), end user, distribution channel, and isotope source.
• Regional outlook covering North America FDA approval pipeline depth, Europe reactor isotope production scale, Asia Pacific cyclotron investment, and emerging market oncology treatment centre procurement.
• Competitive landscape of Bayer AG, Novartis AG, Curium Pharma, NorthStar Medical Radioisotopes, Orano Med, Actinium Pharmaceuticals, and Telix Pharmaceuticals covering isotope supply positions, clinical pipeline depth, and distribution network reach.
• Regulatory analysis covering FDA radiopharmaceutical guidance updates, EMA clinical trial registration requirements, IAEA isotope production standards, NRC licensing requirements, and national nuclear medicine procurement regulations.
• Report delivered in PDF, Excel, and presentation formats supported by validated isotope production data, hospital nuclear medicine procurement benchmarks, and clinical trial expert primary research.

Alpha Emitters Market Definition

The alpha emitters market covers radioisotopes that decay by emitting alpha particles, used in targeted alpha therapy, bone metastasis treatment, and radiopharmaceutical research. Key radionuclides include Actinium-225, Radium-223, Astatine-211, and Lead-212.

Alpha Emitters Market Inclusions

Covers global and regional forecasts from 2026 to 2036 by radionuclide type, application, end user, distribution channel, and isotope source. Includes reactor-produced, cyclotron-produced, and generator-based alpha-emitting isotopes. Covers hospital, cancer centre, research institute, and pharmaceutical company procurement.

Alpha Emitters Market Exclusions

Excludes beta-emitting and gamma-emitting radioisotopes not classified as alpha emitters. Omits finished radiopharmaceutical drug products sold at the formulated drug level. Excludes radiation therapy equipment and delivery devices. Does not cover radioactive waste management services or radiation shielding infrastructure.

Alpha Emitters Market Research Methodology

• Primary Research
  • Interviews with nuclear medicine physicians, radiopharmacy procurement directors, isotope production facility managers, and clinical trial programme executives across key markets.
• Desk Research
  • Uses Bayer AG, Novartis AG, and NorthStar Medical Radioisotopes public filings. Includes NRC licensing data, IAEA isotope production benchmarks, and FDA IND and NDA radioiopharmaceutical approvals from 2024 to 2025.
• Market-Sizing and Forecasting
  • Hybrid top-down and bottom-up model based on isotope production volumes, clinical trial patient enrolment rates, treatment cycle pricing by indication, and radiopharmacy procurement data across end-user segments.
• Data Validation and Update Cycle
  • Validated using regulatory approval records, producer shipment data, and hospital nuclear medicine procurement benchmarks. Cross-checked with expert interviews and updated on a regular cycle.